Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23941182 | 0.80 | MAPT (0.56) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL23940769 | 0.77 | MAPT (0.56) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL23940967 | 0.77 | ALDH1A1 (0.50) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL23926181 | 0.71 | MAPT (0.55) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL25144993 | 0.71 | MAPT (0.51) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL28392917 | 0.70 | ALDH1A1 (0.44) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL23940776 | 0.70 | MAPT (0.50) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL23940768 | 0.70 | MAPT (0.50) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL18781917 | 0.68 | MAPT (0.65) | ADORA3MAPTALDH1A1HPGDLMNA | |
| SCHEMBL9479879 | 0.68 | MAPT (0.65) | ADORA3MAPTALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2021211982-A2 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211982-A2 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | CYP2B6, TYR, CYP2D6 | ADORA3 2216/4885MAPT 4814/4885ALDH1A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.